BR9707638A - Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia. - Google Patents

Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia.

Info

Publication number
BR9707638A
BR9707638A BR9707638-4A BR9707638A BR9707638A BR 9707638 A BR9707638 A BR 9707638A BR 9707638 A BR9707638 A BR 9707638A BR 9707638 A BR9707638 A BR 9707638A
Authority
BR
Brazil
Prior art keywords
iscoms
chosen
pct
immunotherapy
prophylaxis
Prior art date
Application number
BR9707638-4A
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Original Assignee
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein, Bengtsson Karin Loevgren, Jill Ekstroem filed Critical Bror Morein
Publication of BR9707638A publication Critical patent/BR9707638A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Abstract

"PARTìCULA CONTENDO LIPìDEOS, ESCOLHIDAS DENTRE ISCOMS E MATRIZ DE ISCOMS, E, PREPARAçãO DE VACINA PARA PROFILAXIA E/OU IMUNOTERAPIA". As partículas contendo lipídeos como iscoms, matriz de iscoms, ou vesículas, como micelas ou lipossomas que compreendem uma ou mais moléculas de receptor hidrófobo para marcação e substâncias antigênicas, cujas moléculas de receptor foram integradas na partículas e são escolhidas dentre receptores contendo lipídeos ou receptores que são hidrófobos, cujas moléculas de receptor se ligam às substâncias antigênicas.
BR9707638-4A 1996-02-21 1997-02-20 Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia. BR9707638A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600648A SE9600648D0 (sv) 1996-02-21 1996-02-21 Receptorbimdande enhet
PCT/SE1997/000287 WO1997030726A1 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances

Publications (1)

Publication Number Publication Date
BR9707638A true BR9707638A (pt) 2000-01-04

Family

ID=20401482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9707638-4A BR9707638A (pt) 1996-02-21 1997-02-20 Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia.

Country Status (12)

Country Link
US (1) US6027732A (pt)
EP (1) EP0944397B1 (pt)
AT (1) ATE258066T1 (pt)
AU (1) AU718443B2 (pt)
BR (1) BR9707638A (pt)
CA (1) CA2247103C (pt)
DE (1) DE69727314T2 (pt)
DK (1) DK0944397T3 (pt)
ES (1) ES2214608T3 (pt)
NZ (1) NZ331418A (pt)
SE (1) SE9600648D0 (pt)
WO (1) WO1997030726A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ES2572834T3 (es) * 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
NZ518999A (en) * 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
SE0003538D0 (sv) * 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US20050226894A1 (en) * 2002-01-15 2005-10-13 Jensen-Jarolim Erika Oral vaccination
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
PL2486938T3 (pl) 2006-09-26 2018-08-31 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2325243B1 (es) * 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
ES2606563T3 (es) 2009-06-05 2017-03-24 Infectious Disease Research Institute Adyuvantes lipídicos de glucopiranosilo sintéticos y composiciones de vacuna que contienen los mismos
EP2694099B1 (en) 2011-04-08 2019-10-16 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
LT2811981T (lt) 2012-02-07 2019-06-10 Infectious Disease Research Institute Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EA201691348A1 (ru) 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют Однофлаконные вакцинные составы
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403081A1 (fr) * 1977-09-19 1979-04-13 Merieux Inst Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.

Also Published As

Publication number Publication date
WO1997030726A1 (en) 1997-08-28
EP0944397A1 (en) 1999-09-29
NZ331418A (en) 2000-03-27
ES2214608T3 (es) 2004-09-16
CA2247103A1 (en) 1997-08-28
DE69727314D1 (de) 2004-02-26
EP0944397B1 (en) 2004-01-21
AU718443B2 (en) 2000-04-13
SE9600648D0 (sv) 1996-02-21
AU2238397A (en) 1997-09-10
US6027732A (en) 2000-02-22
DK0944397T3 (da) 2004-06-01
DE69727314T2 (de) 2004-11-18
CA2247103C (en) 2009-01-20
ATE258066T1 (de) 2004-02-15

Similar Documents

Publication Publication Date Title
BR9707638A (pt) Particula contendo lipìdeos, escolhidas dentre iscoms e matriz de iscoms, e, preparacao de vacina para profilaxia e/ou imunoterapia.
Sobo-Vujanovic et al. Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells
AU6253898A (en) Use of microparticles combined with submicron oil-in-water emulsions
WO2006026389A3 (en) Ceramide derivatives as modulators of immunity and autoimmunity
WO1999042564A3 (en) Apoptotic cell-mediated antigen presentation to dendritic cells
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
UA49814C2 (uk) Композиція, яка містить антиген вірусу папіломи, спосіб лікування цервікального раку, спосіб лікування гострокінцевої кондиломи
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
WO2005037190A3 (en) Multiplex vaccines
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ES2149340T3 (es) Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
AU697150B2 (en) Use of dioxomorpholines for combating endoparasites, new dioxomorpholines and processes for their preparation
HK1068933A1 (en) Feather-based padding product, preparation method and installation for implementing said method
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
NO981963D0 (no) Influensavaksine-blandinger
DK0680750T3 (da) Kosmetisk eller farmaceutisk sammensætning til topisk anvendelse
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
RU94040856A (ru) Вакцина для перорального введения
DK1317254T3 (da) Retardpartikeldispersion
ATE544470T1 (de) Immuntherapeutische methoden und zusammensetzungen
NZ542328A (en) Use of immune stimulating complex (ISCOM) particles as an adjuvant for an antigenic composition that comprises live micro organisms
DE69120942T2 (de) Hilfsstoffzusammensetzungen in fester form, dispergieren in wässerigen medien
PL315127A1 (en) Deuterised biologically active substances for percutaneous administration
ES2177535T3 (es) Vacunas contra protozoos intestinales.
ES2113734T3 (es) Sistema de forjado para paredes y revestimientos en la construccion.

Legal Events

Date Code Title Description
FF Decision: intention to grant
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
HIFF Patent grant cancelled
FF Decision: intention to grant
HHFI Decision: rectification
HHFI Decision: rectification
FG9A Patent or certificate of addition granted
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 15A, 16A, 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.